Hepion Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

De CEO Hepion Pharmaceuticals is Bob Foster, benoemd in Jun2016, heeft een ambtstermijn van 7.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 725.83K, bestaande uit 73.5% salaris en 26.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.062% van de aandelen van het bedrijf, ter waarde € 16.40K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.8 jaar en 3.6 jaar.

Belangrijke informatie

Bob Foster

Algemeen directeur

US$725.8k

Totale compensatie

Percentage CEO-salaris	73.5%
Dienstverband CEO	7.2yrs
Eigendom CEO	0.06%
Management gemiddelde ambtstermijn	3.8yrs
Gemiddelde ambtstermijn bestuur	3.6yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Bob Foster's beloning veranderd ten opzichte van Hepion Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2023	n/a	n/a	-US$52m
Dec 31 2022	US$726k	US$533k	-US$45m
Sep 30 2022	n/a	n/a	-US$45m
Jun 30 2022	n/a	n/a	-US$46m
Mar 31 2022	n/a	n/a	-US$34m
Dec 31 2021	US$700k	US$500k	-US$33m
Sep 30 2021	n/a	n/a	-US$28m
Jun 30 2021	n/a	n/a	-US$25m
Mar 31 2021	n/a	n/a	-US$22m
Dec 31 2020	US$2m	US$400k	-US$20m
Sep 30 2020	n/a	n/a	-US$18m
Jun 30 2020	n/a	n/a	-US$13m
Mar 31 2020	n/a	n/a	-US$15m
Dec 31 2019	US$621k	US$400k	-US$12m
Sep 30 2019	n/a	n/a	-US$12m
Jun 30 2019	n/a	n/a	-US$20m
Mar 31 2019	n/a	n/a	-US$17m
Dec 31 2018	US$375k	US$312k	-US$18m

Compensatie versus markt: De totale vergoeding ($USD 725.83K ) Bob } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 474.54K ).

Compensatie versus inkomsten: De vergoeding van Bob is gestegen terwijl het bedrijf verliesgevend is.

CEO

Bob Foster (65 yo)

7.2yrs

Tenure

US$725,833

Compensatie

Dr. Robert T. Foster, also known as Bob, B.Sc (Pharm), Pharm D., Ph D., has been Chief Executive Officer at Hepion Pharmaceuticals, Inc. (formerly ContraVir Pharmaceuticals, Inc.) since October 3, 2018, Di...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Robert Foster	President	7.2yrs	US$725.83k	0.062% € 16.4k
John Cavan	Chief Financial Officer	7.4yrs	US$495.33k	0.020% € 5.2k
Todd Hobbs	Chief Medical Officer	2.5yrs	US$578.00k	geen gegevens
Launa Aspeslet	Chief Operating Officer	1.2yrs	geen gegevens	geen gegevens
Sharen Pyatetskaya	Director of Investor Relations	no data	geen gegevens	geen gegevens
Daniel Trepanier	Senior Vice President of Drug Development	3.8yrs	geen gegevens	geen gegevens
Patrick Mayo	Senior Vice President of Clinical Pharmacology	3.8yrs	geen gegevens	geen gegevens
John Sullivan-Bolyai	Part-Time Consultant	5.7yrs	US$34.62k	geen gegevens
Stephen Harrison	Scientific Advisory Board Chair & Consultant Medical Director	3.8yrs	geen gegevens	geen gegevens

3.8yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 336 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Robert Foster	President	4.8yrs	US$725.83k	0.062% € 16.4k
Stephen Harrison	Scientific Advisory Board Chair & Consultant Medical Director	4yrs	geen gegevens	geen gegevens
John Brancaccio	Independent Director	10.3yrs	US$86.00k	0.0092% € 2.4k
Gary Jacob	Independent Chairman of the Board	10.3yrs	US$102.50k	0.016% € 4.2k
Timothy M. Block	Independent Director	9.8yrs	US$77.90k	geen gegevens
Petrus L. Wijngaard	Independent Director	3.2yrs	US$79.50k	0.039% € 10.4k
Rohit Loomba	Member of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens
Nikolai Naoumov	Member of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens
Philippe Gallay	Member of Scientific Advisory Board	7.1yrs	geen gegevens	geen gegevens
Anand Reddi	Independent Director	1.2yrs	US$30.92k	geen gegevens
Yury Popov	Member of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens
Kaouthar Lbiati	Independent Director	1.2yrs	US$30.92k	geen gegevens

3.6yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 336 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.6 jaar).

Hepion Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Hepion Pharmaceuticals, Inc. Appoints Michael Purcell to Its Board of Directors

Hepion Pharmaceuticals, Inc. Announces Resignation of Anand Reddi from the Board of Directors

Hepion Pharmaceuticals, Inc. Announces Resignation of Robert Foster as Director

Hepion Pharmaceuticals, Inc. Announces Resignation of Dr. Todd Hobbs, as the Chief Medical Officer, Effective September 29, 2023

High number of new directors

Hepion Pharmaceuticals, Inc., Annual General Meeting, Aug 05, 2022

Recent updates

Hepion Pharmaceuticals Receives Non-Compliance Letter from Nasdaq Regarding Stockholder's Deficit

Hepion Pharmaceuticals Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(a)(2)

Pharma Two B Ltd. agreed to acquire Hepion Pharmaceuticals, Inc. (NasdaqCM:HEPA) in a reverse merger transaction valued at an implied equity value of approximately $58.5 million.

Hepion Pharmaceuticals, Inc. announced delayed 10-Q filing

Hepion Pharmaceuticals, Inc. Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial

Hepion Pharmaceuticals, Inc. announced delayed annual 10-K filing

Hepion Pharmaceuticals, Inc. Appoints Michael Purcell to Its Board of Directors

Hepion Pharmaceuticals, Inc. Announces Resignation of Anand Reddi from the Board of Directors

Hepion Pharmaceuticals, Inc. Announces Resignation of Robert Foster as Director

Hepion Pharmaceuticals, Inc. announced delayed 10-Q filing

Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-Week Phase 2 Study of Advanced (F3) Mash Liver Disease

Hepion Pharmaceuticals, Inc. Announces the Publication of New Research Study in Mice

Hepion Pharmaceuticals, Inc. announced that it has received $5.000004 million in funding

Hepion Pharmaceuticals, Inc. Announces Results from A Study with in Which the Anti-Cancer Activity of Hepion's Lead Drug Candidate, Rencofilstat

Hepion Pharmaceuticals, Inc. Announces Positive Results from Translational Research Study

Hepion Pharmaceuticals, Inc. Announces Resignation of Dr. Todd Hobbs, as the Chief Medical Officer, Effective September 29, 2023

Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial of Rencofilstat

Hepion Pharmaceuticals, Inc. Announces Positive Topline Results from Its Recently Completed Phase 2 Altitude-Nash Clinical Trial

High number of new directors

Hepion Pharmaceuticals, Inc. Announces Positive Results of Preclinical Studies Examining Rencofilstat as A Potential Therapeutic for Multiple Myeloma

Hepion Pharmaceuticals, Inc. Presents of Preclinical Study Highlighting Anti-Cancer Activity of Rencofilstat in Combination with Proteosome Inhibitors

Hepion Pharmaceuticals Receives 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirements

Hepion Pharmaceuticals Announces Early Completion of Enrollment in Phase 2 'Altitude-Nash' Liver Function Trial

Hepion Pharmaceuticals, Inc. Announces Publication of Phase 2A 'Ambition' Clinical Trial Results

Hepion Pharmaceuticals, Inc. Announces Initiation of Dosing in Phase 2 'ALTITUDE-NASH' Liver Function Trial

Hepion Pharmaceuticals, Inc. Announces Initiation of Phase 2b ‘ASCEND-NASH’ Trial

Hepion Pharmaceuticals, Inc., Annual General Meeting, Aug 05, 2022

Hepion Pharmaceuticals, Inc. Announces Board Changes

Hepion Pharmaceuticals, Inc. Appoints Dr. Launa J. Aspeslet as Chief Operating Officer

Hepion Pharmaceuticals Receives Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard from Nasdaq

Hepion Pharmaceuticals Announces Clinical Collaboration with HepQuant in Phase 2b NASH Trial

Hepion Pharmaceuticals, Inc., Annual General Meeting, Jun 24, 2022

Hepion Pharmaceuticals, Inc. announced delayed annual 10-K filing

Hepion Pharmaceuticals Appoints Eddie C. Cheung to Lead the Company’s Strategic Medical Affairs in Asia

Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer

Hepion Pharmaceuticals, Inc Announces Additional Efficacy Data from Its Phase 2A Ambition Clinical Trial

Hepion Pharmaceuticals, Inc. Announces Positive Topline Data from Phase 2A ‘Ambition’ Nash Trial and Achieve All Primary Endpoints

Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2A 'AMBITION' Clinical Trial of CRV431 for the Treatment of Advanced NASH

Hepion Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $88.4 million.

Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer

Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation with Final Dose Cohort in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH

Hepion Pharmaceuticals’ CRV431 Demonstrates Additional Potential Advantage in Liver Disease

Hepion Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.

Hepion Pharmaceuticals Terminated the At Market Issuance Sales Agreement with B. Riley FBR, Inc

New 90-day low: €2.22

Hepion Pharmaceuticals, Inc.'s Data Safety Monitoring Board Recommends Continuation of Phase 2A 'Ambition' Clinical Trial for Treatment of Advanced Nash

New 90-day low: €2.44

Hepion Pharmaceuticals Introduces Proprietary A.I. Platform for Drug Development

Hepion Pharmaceuticals Reports Positive Activity of CRV431 Against Coronavirus SARS-2 in Study Conducted by the National Institute of Allergy and Infectious Diseases

New 90-day high - €3.76

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd